Even in healthy women, increased insulin resistance has been reported during the luteal phase of the menstrual cycle in healthy women (62)
In contrast, those with PCOS or underlying conditions have seen improved cycle regularity, Dr
RiskBenefit Perspective Despite theoretical concerns, the clinical reality is clear: GLP-1 therapies produce substantial weight loss Improve glycemic control and cardiometabolic outcomes Reduce cardiovascular risk in multiple studies When evaluating carcinogenicity risk, current evidence suggests: Strong rodent signals exist but may not translate to humans Long-term human data has not confirmed increased thyroid cancer risk Regulatory warnings remain precautionary rather than confirmatory Conclusion The GLP-1 receptor agonist classfrom Liraglutide to next-generation oral agents like Orforglipronrepresents one of the most transformative areas in metabolic medicine
We are currently working to expand our coverage
Results continue if the plan remains consistent
Hims & Hers will now start selling Wegovy and Ozempic, both of which are based on the molecule Semaglutide, to its customers instead of copies of the two drugs